Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

NCT03746522 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Bardet Biedl Syndrome (BBS)
Alström Syndrome (AS)

Interventions

DRUG: Setmelanotide
DRUG: Placebo

Sponsor

Rhythm Pharmaceuticals, Inc.